In a cohort of 433 patients with primary sclerosing cholangitis (PSC), Wannhoff et al. stratified individuals based on FUT2 and FUT3 activity, revealing significant differences in median CA19‐9 levels of cancer‐free patients: 2.0 U/mL (no FUT3 activity), 17.0 U/mL (functional FUT2 and FUT3), and 37.0 U/mL (nonfunctional FUT2 with active FUT3) (p < 0.001) [21]. This evidence concerns the gene FUT2 and cancer.